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Four new medicines—liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/
topiramate—have been recently added to the pharmacological arsenal for obesity
treatment and could represent important tools to manage this epidemic disease. To
achieve satisfactory anti‐obesity goals, the use of these new medicines should be
optimized and tailored to specific patient subpopulations also by applying dose adjust-
ments if needed. In the present review, we posit that gender could be among the
factors influencing the activity of the new obesity drugs both because of pharmacoki-
netic and pharmacodynamic factors. Although evidence from premarketing clinical
studies suggested that no dose adjustment by gender is necessary for any of these
new medicines, these studies were not specifically designed to identify gender‐
related differences. This observation, together with the strong theoretical background
supporting the hypothesis of a gender‐dimorphic response, strongly call upon an
urgent need of new real‐life data on gender‐related difference in the pharmacology
of these new obesity drugs.
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Obesity is a gender dimorphic disease.1 Indeed, there are differences
in its prevalence, pathophysiology, clinical presentation, and natural
history between men and women. The worldwide prevalence of obe-
sity is higher in women than in men (15% vs 11% in 2016).2 Excess fat
distribution is also different between males and females, being con-
centrated mainly in centrally located visceral areas in men and subcu-
taneously in women.3 Moreover, obesity increases cardiovascular riskAMPK, AMP‐kinase; CRH,
ne transporter; DEA, Drug
icinal Agency; ER, oestradiol
MO, flavin mono‐oxygenase;
P kinase/ERK kinase; NAc,
er; PIP2, phosphatidylinositol
; RCT, randomized clinical
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wileyonlinelibrary.com/jmore in men than women, possibly because visceral fat worsens insu-
lin resistance, lipid profile, and fluid metabolism much more than sub-
cutaneous fat.1
Nevertheless, very few studies addressed the question of whether
gender also contributes to the response to anti‐obesity treatment. A
meta‐analysis of 58 published studies4 showed a higher decrease in
body weight in response to diet and lifestyle changes in men than in
women, although the weight loss difference was small. Likewise, body
weight decreased more in men than in women in about 50% of the
studies on bariatric surgery, lifestyle, or diet treatment examined by
Stroebele‐Benschop et al,5 whereas no gender difference emerged in
the remaining. The systematic review published by Robertson et al6
as part of the ROMEO (Review Of MEn and Obesity) study also
reported gender‐related differences in therapeutic responses, with
men responding better to some interventions and women to others.
For years, the only approved drugs for the treatment of obesity
have been amphetamines and orlistat in the United States and orlistat© 2018 World Obesity Federationournal/obr 375
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investigated in the case of amphetamines, whereas conflicting results
have been obtained with orlistat.7-9 In the last years, four new pre-
scription drugs enriched the pharmacological arsenal against obesity
in the United States: liraglutide, lorcaserin, bupropion/naltrexone,
and topiramate/phentermine.10 Two of these medicines, liraglutide
and bupropion/naltrexone, have been approved also by the European
Medicines Agency (EMA) and are thus already available for clinical use
in some countries of the European Community. The gender depen-
dence of the clinical response to these new drugs has been only mar-
ginally investigated. However, as described in Figure 1 and extensively
reported in the next sections, both pharmacodynamic (Table 1) and
pharmacokinetic (Table 2) arguments suggest that gender could signif-
icantly influence the effect of these new medicines.2 | LIRAGLUTIDE
Liraglutide is a glucagon‐like peptide 1 (GLP1) derivative that differs
from human GLP1 because of the substitution of a lysine at position
34 and of the binding of a palmitic acid fatty chain to lysine 26
through a glutamic acid spacer.48 Because of these modifications,
liraglutide is more stable than GLP1 in plasma and strongly binds to
plasma proteins. Liraglutide has been originally approved for the treat-
ment of type II diabetes. Because a substantial weight loss was
noticed in patients with diabetes treated with this drug, the hypothe-
sis that liraglutide could be used for weight reduction in patients with
obesity was raised and formally demonstrated in randomized clinical
trials finally leading to its approval as an anti‐obesity drug.67,68 The
retrospective analysis of these preregistration clinical trials showed
that liraglutide‐induced weight loss was larger in women than in
men at all dosages up to 3 mg; importantly, in men the dose‐response
curve did not plateau at this concentration, suggesting that men couldFIGURE 1 Schematic representation of the mechanisms potentially contr
drugs at each anatomical sitebe less sensitive to liraglutide than women.49 Both pharmacodynamic
and pharmacokinetic factors could be responsible for this gender‐
related difference as detailed in the next sections.2.1 | Pharmacodynamics
Liraglutide pharmacodynamics is very complex because this drug acts at
different levels to affect glucose homeostasis, pancreatic ß‐cells sur-
vival, insulin secretion, and feeding behaviour. Liraglutide acts by
interacting with Gs‐coupled GLP‐1 receptors (GLP‐1R), which belong
to the GPCR B1 subfamily (secretin receptor family).11 GLP‐1R is part
of a multimolecular complex that includes the progesterone receptor
membrane component 1 (PRMC1), a member of the membrane‐
associated progesterone receptor protein family.12 Although it is still
unclear whether PRMC1 may transduce physiologically relevant
progesterone‐dependent signals, the evidence that a progesterone
binding protein is physically associated to the GLP‐1R represents a first
hint that sex steroids could modulate GLP‐1 activity. Additional indica-
tions of a possible role of gender in GLP‐1 physiology are that proges-
terone induces GLP‐1 secretion in cultured enteroendocrine cells
in vitro and in mice in vivo13 and that testosterone enhances insulin
secretion in pancreatic ß‐cells by potentiating GLP‐1 signal transduc-
tion at a postreceptor level in a cAMP/PKA dependent manner.14
The anorexigenic effect of GLP‐1 agonists is exerted at the level of
the central nervous system where GLP‐1 physiologically controls the
activity of brain regions involved in feeding behaviour. Among them, a
crucial role has been attributed to the arcuate nucleus where GLP‐1
directly stimulates anorexigenic proopiomelanocortin (POMC)/
cocaine‐ and amphetamine‐regulated transcript (CART) neurons and
indirectly inhibits orexigenic neuropeptide Y (NPY) and agouti‐related
peptide (AgRP) neurons.69 In addition, GLP‐1 and GLP‐1R agonists are
also involved in the control of food reward through GLP‐1Rs expressedibuting to gender‐related differences in the activity of the anti‐obesity
TABLE 1 Mechanisms of action of the new anti‐obesity drugs: Influence of gender‐related factors
Mechanism of Action Gender‐Related Factors References
Liraglutide Activation of anorexigenic POMC/CART
neurons
Inhibition of orexigenic neuropeptide Y
(NPY) and agouti‐related peptide
(AgRP) neurons
Reduced food reward
Slowing of gastric emptying
Association of plasma membrane progesterone receptors
to GLP1 receptor in a multimolecular complex
Progesterone control of GLP‐1 release in humans
GLP‐1 dependent androgen control of insulin secretion
Oestrogen‐dependence of central exendin anorectic
effect
Gender difference in gastric emptying
11-17
Lorcaserin Stimulation of anorexigenic POMC/CART
neurons
Oestradiol‐dependent modulation of serotoninergic
neurotransmission at multiple levels (serotonin synthesis
and expression of serotonin receptors and transporters)
The anorectic effect of serotoninergic drugs in experimental
animals is oestrogen‐dependent
18-28
Naltrexone/bupropion combination
Naltrexone Blockade of μ‐opioid receptors on POMC
neurons
Blockade of β‐endorphin autofeedback on
POMC neurons
Oestradiol‐dependent desensitization of μ‐opioid receptors
in anorexigenic hypothalamic POMC neurons
Gender difference in the hypothalamic–pituitary–adrenal
axis response to naltrexone
Gender difference in the clinical response
to naltrexone in alcohol dependence
29-33
Bupropion Central anorexigenic effects:
Inhibition of DA and NE reuptake
Stimulation of POMC neurons in the
arcuate nucleus
Oestradiol‐dependent regulation of the expression of both
DAT and D2 receptors
Oestradiol‐mediated potentiation of bupropion
antidepressant effect
34-39
Phentermine/topiramate combination
Phentermine Enhanced DA and NE release in the
hypothalamus by the combined
blockade of DAT, NET, VMAT,
and MAO
Oestrogen‐dependent regulation of MAO, NET, DAT,
and VMAT expression
Higher NE‐induced lipolysis in women
40-43
Topiramate Potentiation of leptin and insulin
signalling in the hypothalamus
Enhancement of insulin sensitivity
in skeletal muscles
Oestrogenic control of AMPA receptor expression 44-47
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key nodes of the central reward circuitry.70 Functional magnetic reso-
nance imaging (fMRI) studies showed that other brain regions such as
insula, amygdala, and orbitofrontal cortex are also involved in food
reward mechanisms and that their activation in response to food
pictures is strongly reduced by the administration of GLP‐1 antago-
nists.71 Evidence is starting to accumulate that central GLP‐1 effect
could be modulated by sex steroids. For instance, Richard et al72
showed that female rats are more sensitive than males to the anorexi-
genic effect of a centrally administered GLP‐1R agonist (exendin‐4)
and that this gender difference is abrogated by antioestrogens. The
oestrogen modulation of GLP‐1 anorexigenic activity could involve
VTA and NAc considering that the anorexigenic effect of oestradiol is
at least in part exerted at the level of these brain structures.15
An additionalmechanismof liraglutide anorexigenic effect is the abil-
ity of this drug to activate gastric vagal afferents, thereby slowing gastric
emptying and promoting an early sense of satiety via central mecha-
nisms.16 Although it is well established that gastric emptying is slower
in women than in men,17 no study has yet addressed the gender‐
dependence of liraglutide effect on this process.2.2 | Pharmacokinetics
Data from preregistration clinical trials showed that liraglutide expo-
sure was about 32% higher in women than in men after adjusting forbody weight; although the mechanism involved was not directly inves-
tigated, a higher rate of drug degradation in men when compared with
women may explain this phenomenon.50 Noteworthy, this difference
in liraglutide disposition could account for about 50% of the greater
weight loss induced by 3‐mg liraglutide in women when compared
to men.493 | LORCASERIN
Lorcaserin is a highly specific agonist of the 5HT2C receptors, the
receptor subtype responsible for serotonin anorectic effect.18 In fact,
lorcaserin reduces appetite without triggering valvular heart defects
or pulmonary hypertension, both serious unwanted effects associated
to the stimulation of other serotonin receptors and which led to the
withdrawal from the market of the old anorectic serotonin reuptake
inhibitor d‐fenfluramine.18
Lorcaserin was approved by the Food and Drug Administration
(FDA) in 2012 based on the results of three randomized clinical trials
(RCT) that enrolled both men and women. These RCT, not
specifically designed to investigate gender differences, did not find
any difference in lorcaserin response between males and females
and therefore, no gender‐related adjustment was deemed necessary
with this drug.73,74 In contrast with these findings, Anderson et al75
reported that men lose more weight than females while on lorcaserin,
whereas Kolotkin et al76 found a higher improvement in quality of life
TABLE 2 Pharmacokinetics of new anti‐obesity drugs: Influence of gender‐related factors
PK profile Gender‐Related Factors References
Liraglutide Subcutaneous administration
Slow absorption from the injection site
Strong plasma protein binding (>98%)
Small distribution volume
Degraded in small peptides
Clearance: 1.2 L/h
Half‐life: 13 h
Drug exposure about 32% higher in women than
in men
Higher drug degradation in men (?)
48-50
Lorcaserin Oral administration
Tmax: 1.5‐2 h
Liver metabolism to inactive metabolites by CYP3A4, CYP2D6
and FMO
Metabolites eliminated with urines
Half‐life: 1.8 h
Available as an extended release formulation for one‐daily
administration
Higher CYP2D6 and FMO expression in women 51-54
Naltrexone/bupropion combination
Bupropion Oral administration
Tmax: 3 h
Strong plasma protein binding (>80%)
Large distribution volume with accumulation in the
adipose tissue
Liver metabolism by CYP2B6 to the active metabolite
hydroxy‐bupropion
Urinary elimination
Higher CYP2B6 expression in women
Higher drug exposure in women among patients
treated for depression or smoking cessation
34,55-57
Naltrexone Oral administration
High hepatic first pass effect and low oral bioavailability (5‐40%)
Low plasma‐protein binding (~20%)
Large distribution volume (1350 L) with accumulation in the
brain, spleen, and adipose tissue
Liver metabolism by dihydrodiol dehydrogenase to the active
metabolite 6β‐naltrexol
Half‐life: 4 h
Clearance: 3.5 L/min
Inhibition of dihydrodiol dehydrogenase by
androgens that are also substrates of this enzyme
Higher naltrexone and 6β‐naltrexol concentrations
in women
Higher naltrexone to 6β‐naltrexol ratio in women
34,58-61
Phentermine/topiramate combination
Topiramate Oral administration
High oral bioavailability (>80%)
Tmax: 1.8‐4.3 h
An extended release formulation with longer Tmax is available
and used in the combination with phentermine
Half‐life: 19‐23 h
Low plasma protein binding (13‐17%)
Distribution volume: 0.6‐0.80 L/kg
Most of the drug is excreted unmodified in the urine
Higher drug exposure in female than in male rats
Values of distribution volume for females about
50% of those for males
62,63
Phentermine Oral administration
High oral bioavailability
Tmax: 3‐4.4 h
Low plasma protein binding
Distribution volume: 3‐4 L/kg
Most of the drug (62.7‐84.8%) excreted unmodified in the urine
No data available 64-66
378 CATALDI ET AL.in female than in male patients with obesity primarily because of a
larger effect on BMI. While the the existence of a gender difference
in the clinical response to lorcaserin is still debated, intrinsically
gender‐dimorphic pathophysiological mechanisms seem to be targeted
by this drug, as discussed in the next section.3.1 | Pharmacodynamics
As mentioned before, lorcaserin acts by selectively potentiating the
serotoninergic neurotransmission at postsynaptic 5HT2C receptors.
Intriguingly, serotoninergic neurotransmission is also modulated by
oestradiol, which has a significant anorectic effect in rats,58 and this
sex hormone influences the anorectic effect of serotoninergic drugs.Indeed, in female rats, low fenfluramine doses decrease food intake
only when given during estrus but not during diestrus,19 and in ovari-
ectomized rats, this anorectic effect is increased by the administration
of oestradiol benzoate.20 The oestradiol‐dependent enhancement of
serotonin anorectic effect is explained by the ability of this hormone
to potentiate the serotoninergic neurotransmission at different levels.
In fact, oestrogen receptors are expressed in serotoninergic neurons21
and oestradiol increases the expression of tryptophan hydroxylase and
decreases the expression of serotonin transporters in midbrain seroto-
ninergic neurons.22,23 Oestradiol increases the expression of serotonin
5HT1A and 5HT2A receptors, two effects mediated by different
oestradiol receptors (ER), ERα and ERβ, respectively,24,25 while con-
flicting results have been obtained on 5HT2C expression in the hypo-
thalamus.26-28 In addition, Rivera et al28 suggested that oestradiol
CATALDI ET AL. 379could potentiate the anorectic effect of selective 5HT2C agonists by
increasing the expression of 5HT2C receptors in the caudal hindbrain
and not in the hypothalamus, whereas Qiu et al78 hypothesized that
oestradiol and serotonin could interact at a postreceptor level. More
specifically, these authors demonstrated that both oestradiol and
5HT2C agonists reduce the ability of the GABAB agonist baclofen to
activate G‐protein–coupled inwardly rectifying K+ channels (Kir) in
POMC neurons of the arcuate nucleus and speculated that the activity
of these neurons could be enhanced in vivo by a similar effect, namely,
the attenuation of tonic GABAB‐dependent inhibition.
79 The molecu-
lar mechanism responsible for both serotonin‐ and oestrogen‐
dependent attenuation of GABAB‐dependent Kir activation seems to
involve the depletion of plasma membrane phosphatidylinositol 4,5‐
bisphosphate (PIP2), possibly triggered by activation of Gq‐coupled
plasma membrane receptors.79
In conclusion, there is evidence that, at least in the rat, oestradiol
and serotonin 5HT2c receptors control feeding via a converging signal-
ling mechanisms, thus establishing a robust rationale for possible
gender‐related effects in the action of lorcaserin.3.2 | Pharmacokinetics
The pharmacokinetics of lorcaserin is summarized in Table 2 and more
details can be found in previous studies.51,52 Two of the main enzymes
involved in the metabolism of lorcaserin, CYP2D6 and flavin mono‐
oxygenase (FMO), have a higher expression in women than in men;
however, the impact of this gender difference on lorcaserin metabo-
lism remains to be investigated.53,54 However, preregistration popula-
tion pharmacokinetic studies, though not specifically designed to
identify gender differences, showed that lorcaserin disposition was
affected by body weight, the presence of diabetes, and the drug for-
mulation used but not by gender.514 | NALTREXONE/BUPROPION
COMBINATION
Bupropion and naltrexone are marketed as a combination in a single
medicine to take advantage of their pharmacological synergism in
suppressing appetite and lowering body weight.34 A higher body
weight–lowering effect was observed in females in preregistration
clinical trials, but no gender‐related dose adjustment was deemed nec-
essary by regulatory agencies.80 Both pharmacodynamic and pharma-
cokinetic factors could account for gender‐related differences in the
activity of this drug combination.4.1 | Pharmacodynamics
Bupropion is an antidepressant that is structurally related to the indi-
rect sympathetic agonist diethylpropion and blocks the presynaptic
transporters for dopamine (DAT) and noradrenaline (NET).34,35 The
consequent increase in the concentration of these transmitters at
the synaptic cleft in the hypothalamus is responsible for bupropion
anorectic effect.36 Indeed, dopaminergic and noradrenergic terminals
located in the arcuate and in the paraventricular nuclei control hungerand satiety.81,82 Most of the effects of hypothalamic monoaminergic
systems on feeding are supposed to converge on the regulation of
POMC neurons that represent key mediators of anorexigenic
responses.83 An additional mechanism by which bupropion‐induced
enhancement of dopaminergic neurotransmission could elicit an ano-
rectic response is the regulation of the central reward pathways, as
suggested by the ability of dopaminergic antagonists to abrogate the
anorectic effect of diethylpropion when infused into the NAc.84
The evidence that the expression of dopamine receptors and
transporters in the central nervous system is strongly modulated by
sex steroids represents a theoretical premise for a possible gender
dimorphic response to bupropion. It has been reported, indeed, that,
in rats, ovariectomy lowers the expression not only of D2 dopamine
receptors but also of DAT in the NAc, caudate nucleus, and in the cin-
gulate cortex, whereas chronic treatment with oestrogens reverts
these changes.37 In neurons, oestrogens also directly enhance DAT
activity in a protein kinase C (PKC)‐ and MAP kinase/ERK kinase
(MEK)‐dependent manner.38 An additional mechanism by which
oestrogens further enhance dopamine uptake in neurons is the
increase in the availability of this neurotransmitter for neuronal DAT
through the inhibition of its astrocytic uptake.85 Although the effect
of oestrogens on the anorexigenic mechanism of bupropion has not
been investigated so far, published data demonstrate that these hor-
mones do potentiate the antidepressant activity of this drug.39
Naltrexone, the other component of the bupropion/naltrexone
combination, is an orally active antagonist of μ‐, κ‐, and δ‐opioid recep-
tors approved for the treatment of opioid and alcohol addiction.29,86
Although the endogenous opioid system controls feeding behaviour
and opioid agonists and antagonists, respectively, increase and
decrease feeding in experimental animals,87 naltrexone was not added
to bupropion in the naltrexone/bupropion combination to take advan-
tage of its weak anorectic activity in humans.88 Instead, the pharmaco-
logical synergism of naltrexone with bupropion is related to the ability
of naltrexone to counteract an opioid‐dependent feedback mechanism
that limits the effect of bupropion on POMC‐neurons.30,31 This
autoinhibitory mechanism physiologically regulates POMC‐neuron
activity through the release of the POMCderivative β‐endorphin which
activates μ‐opioid receptors,89 as also indicated by the increase in
POMC gene expression in the hypothalamus that occurs when opioid
receptors are chronically blocked with naltrexone.90
It is expected that this mechanism by which naltrexone increases
bupropion anorectic effect could show gender‐related differences.
Indeed, it has been clearly demonstrated that μ‐opioid receptors in
the hypothalamus are modulated by oestrogens. More precisely,
oestradiol desensitizesμ‐opioid receptors in anorexigenic hypothalamic
POMC neurons upon binding to plasma‐membrane Gq‐mER recep-
tors.91,92 This effect is exerted downstream the opioid receptor and
does not involve changes in ligand affinity.92 Although whether
oestradiol modifies the response to naltrexone/bupropion in obesity
still needs to be established, gender‐related differences have been
reported for other effects of naltrexone such as the acute stimulation
of the hypothalamic‐pituitary‐adrenal axis32 or alcohol weaning.33
New information on the mechanism responsible for the central anorex-
igenic effect of the naltrexone/bupropion combination are beginning to
emerge from fMRI studies; using this technique, Wang et al93 showed
380 CATALDI ET AL.that the naltrexone/bupropion combination attenuates the activation
of the hypothalamus in response to food visual cues while enhancing
at the same time the activation of cortical regions involved in inhibitory
control (anterior cingulate), internal awareness (superior frontal, insula,
superior parietal), and memory (hippocampal). These data, therefore,
support the idea that, in humans, additional regions besides those iden-
tified in rodents are modulated by the naltrexone/bupropion combina-
tion, yielding to a much more complicated scenario than initially
thought, whose modulation by gender remains to be investigated.4.2 | Pharmacokinetics
The main pharmacokinetic properties of bupropion and naltrexone are
summarized in Table 2 and further details can be found in Jefferson
et al94 and Bullingham et al.58
Gender could affect bupropion pharmacokinetics at the level of
both drug metabolism and distribution. Bupropion is hydroxylated in
the liver to its active metabolite hydroxy‐bupropion by CYP2B6 that
is, indeed, potently induced by oestrogens as also indicated by its
higher levels in females as compared with males.55,56 Although
oestrogen‐dependent CYP2B6 induction may decrease drug exposure
in women as compared with men, other gender‐related factors can
counterbalance this effect. More specifically, bupropion accumulates
in fat because of its high lipophilicity, and therefore, drug AUC tends
to be higher in women than in men.
The hypothesis that gender‐related differences may influence the
pharmacokinetics of bupropion has been already examined in past
studies with controversial results. For instance, while Findlay et al95
did not find any difference between sexes in bupropion pharmacoki-
netics, Stewart et al57 observed a different bupropion and hydroxyl‐
bupropion pharmacokinetic profile in male and female adolescents
taking bupropion for smoking cessation. They found that the AUC
and Cmax of both bupropion and hydroxy‐bupropion were significantly
higher in females than in males. Interestingly, bupropion distribution
volume and half‐life were both higher in females than in males
whereas no difference was observed in drug clearance. More recently,
Laib et al96 performed a cross‐sectional study among depressed
patients treated with bupropion with the aim of validating an HPLC
technique for the therapeutic drug monitoring of this antidepressant
through the measurement of hydroxy‐bupropion plasma levels. The
results of this study seem to confirm the hypothesis of a significant
gender dimorphism in bupropion pharmacokinetics because higher
bupropion plasma levels were found in female than in male patients.
Gender‐related differences in naltrexone pharmacokinetics have
also been reported. In patients taking this drug as an adjunct to nico-
tine patch for smoking cessation, the plasma concentrations of the
main naltrexone metabolite 6β‐naltrexol, which has about a half
potency of the parental compound in blocking μ‐opioid receptors,
were higher in women than in men.59 Similar results were obtained
by Liu et al60 in patients with chronic pain taking naltrexone for opioid
weaning. A possible explanation for these findings is that testosterone
and dihydrotestosterone are both substrates and the most potent
competitive inhibitors of dihydrodiol dehydrogenases responsible for
naltrexone conversion into 6β‐naltrexol.61The effect of gender on the plasma levels of bupropion,
hydroxybupropion, erythrohydrobupropion, threohydrobupropion,
naltrexone, and 6β‐ naltrexol after the administration of the
bupropion/naltrexone combination have been examined in the Clinical
Pharmacology and Biopharmaceutics Review(s) of the FDA new drug
application for this medicine.97 A significant effect of gender was
found on the ratio between bupropion clearance (Cl) and bioavailabil-
ity (F) (Cl/F), but it was considered too small to warrant gender‐related
dose adjustment.5 | PHENTERMINE/TOPIRAMATE
COMBINATION
A fixed combination of phentermine and extended release topiramate
has been approved by the FDA98 in 2012, whereas the EMA refused
its marketing authorization because of safety concerns.99 Both these
drugs cause weight loss even when administered separately and no
formal demonstration of a real synergism between them has been
obtained so far.100 The reason why phentermine and topiramate have
been combined in a single pill is related to their different pharmacoki-
netics: Phentermine acts rapidly but for a short time, whereas
topiramate activity has a slower onset but a longer duration; therefore,
by combining phentermine and topiramate a prolonged clinical effect
can be obtained.101 Data from preregistration clinical trials showed
that “the treatment effect of phentermine/topiramate on percent
weight loss was numerically larger for women.”1025.1 | Pharmacodynamics
Topiramate is a sulfamate‐substituted monosaccharide currently
approved for epilepsy and for migraine prophylaxis whose ability to
induce weight loss was fortuitously discovered in clinical trials evaluat-
ing the drug in the aforementioned indications.103 Topiramate has a
very complex pharmacology as it affects multiple targets whose rele-
vance in determining specific drug effects is often unclear. More spe-
cifically, it blocks neuronal voltage‐gated Na+ and Ca2+ channels and
AMPA/kainate receptors, increases the activity of GABAA receptors
and inhibits carbonic anydrase.104 The weight‐lowering mechanism
of topiramate remains uncertain, but seems to involve both central
and peripheral targets. Topiramate acts peripherally by enhancing
insulin sensitivity and activating AMP‐kinase (AMPK) and acetyl‐CoA
carboxylase in skeletal muscles,44,45 whereas its central effect is
mainly exerted in the hypothalamus where it potentiates both leptin‐
induced Jak‐Stat and MAPK/ERK and insulin‐induced insulin receptor
substrate/Akt/forkhead box O1 pathway activation.46 These effects
on leptin and insulin signalling ultimately lead to an increase in the
transcription of genes encoding for anorectic peptides including
POMC, thyrotropin‐releasing hormone (TRH), and corticotropin‐
releasing hormone (CRH).46 Topiramate‐induced AMPA receptor
inhibition could also have a role in the anorectic activity of this drug
considering that the stimulation of hypothalamic AMPA receptors
induces feeding in rats.105 The evidence that oestrogens control
hypothalamic AMPA receptor expression47 suggests that topiramate
anorectic efficacy could be different between men and women.
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efficacy in stopping smoking addiction,106 but not for other
topiramate effects also including the decrease in body weight
observed in epileptic patients.107
Phentermine is a substituted amphetamine, and as such, it
increases adrenergic and dopaminergic neurotransmission by the inhi-
bition of noradrenaline and dopamine recapture and the promotion of
their presynaptic release.108 Therefore, phentermine anorectic effect
can be ultimately explained by an enhancement of catecholaminergic
hypothalamic neurotransmission as described before for bupropion.
Peripheral lipolytic effects also contribute to phentermine‐induced
weight loss. Addiction potential is believed to be significantly lower
with phentermine than with other amphetamines,109 and therefore,
the US Drug Enforcement Administration (DEA) included this drug in
schedule IV of addiction substances. Phentermine was approved by
the FDA for human obesity in 1959 and still ranks among the first
200 more prescribed drugs in the United States110 in 2018. On the
contrary, amphetamines cannot be used for obesity in EU countries
because they have been banned for their cardiovascular toxicity and
addiction potential.
Sex steroids modulate the expression of monoamino‐oxidases,
noradrenaline and dopamine transporters, and vesicular monoamine
transporters,40-42 and this could account for the gender differences
observed in amphetamines and cocaine psychostimulant effect.111,112
It is well established, indeed, that the addiction potential of these
drugs is higher in females than in males both in experimental animals
and in humans.113 Gender differences in body weight response to
amphetamines have not been systematically explored. However, the
anorectic response to methylphenidate, a psychostimulant that shares
with amphetamines the ability to block NET and DAT,114 seems to dif-
fer between genders. For instance, treatment with this drug lowers
body weight faster in male than in female rats and reduces total fluid
intake in male only.115 In addition, in normal‐weight humans, methyl-
phenidate decreases energy intake more in men than in women,116
whereas in patients with obesity, it significantly reduces appetite,
cravings, and snack‐food intake only in women.117 A stronger anorec-
tic effect in women than men has been observed in the response to
methylphenidate also in binge eating disorders.118 Finally, a tendency
for a greater weight loss in women than in men was observed in a
recent pilot study that explored the effect in obesity of
dexamphetamine, an amphetamine approved in 2015 by FDA for the
treatment of binge eating disorders.116 Not only the central anorectic
but also the peripheral effect of amphetamines could be gender‐
related as suggested by the evidence that the infusion of moderate
doses of epinephrine and/or norepinephrine induces a larger lypolytic
effects in women than in men.435.2 | Pharmacokinetics
Studies on the pharmacokinetics of topiramate and phentermine given
together in a single pill have been performed as part of the
preapproval characterization of this new medicine.62,119 These studies
showed that phentermine does not affect topiramate pharmacokinet-
ics, whereas topiramate does increase phentermine exposure in ratsand men but not in dogs. No gender‐related difference in phentermine
pharmacokinetics was observed in dogs, whereas in rats, the exposure
to topiramate was higher in females possibly because the drug is less
metabolized than in males.62,120 Although in humans the distribution
volume of topiramate given alone is about twofold higher in males
than in females,63 population pharmacokinetic studies did not show
any significant effect of gender on the exposure to either phentermine
or topiramate after the administration of the combined pill, and based
on these pharmacokinetic findings, the FDA reviewers did not recom-
mend any dose adjustment based on gender.1196 | CONCLUSION
In the present work, we have reviewed the available evidence on gen-
der dimorphism in the pharmacology of new anti‐obesity drugs. Many
pharmacokinetic and pharmacodynamic factors stand out as poten-
tially responsible for relevant gender‐related differences in the effects
of these drugs. Nonetheless, the clinical trials performed so far, though
enrolling both men and women, were not specifically designed to
identify gender‐related differences, as these were explored only as a
covariate, leading to the perception that no gender‐dependent adjust-
ment is necessary. On the basis of the issues herein highlighted,
gender‐related differences in the efficacy and toxicity of these drugs
need to be urgently explored with specifically designed real‐life stud-
ies. Given the great social relevance of obesity therapeutics, the iden-
tification of gender related variables is likely to allow precise patient
stratification to improve personalized pharmacological treatment with
these new drugs.
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